{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:54:35Z","timestamp":1790268875168,"version":"4.1.0"},"reference-count":53,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Irregular menstrual cycles are associated with increased cardiovascular mortality. Polycystic ovary syndrome (PCOS) is characterized by androgen excess and irregular menses; androgens are drivers of increased metabolic risk in women with PCOS. Combined oral contraceptive pills (COCPs) are used in PCOS both for cycle regulation and to reduce the biologically active androgen fraction. We examined COCP use and risk of dysglycemia (prediabetes and type 2 diabetes) in women with PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Using a large U.K. primary care database (The Health Improvement Network [THIN]; 3.7 million patients from 787 practices), we carried out a retrospective population-based cohort study to determine dysglycemia risk (64,051 women with PCOS and 123,545 matched control subjects), as well as a nested pharmacoepidemiological case-control study to investigate COCP use in relation to dysglycemia risk (2,407 women with PCOS with [case subjects] and without [control subjects] a diagnosis of dysglycemia during follow-up). Cox models were used to estimate the unadjusted and adjusted hazard ratio, and conditional logistic regression was used to obtain adjusted odds ratios (aORs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The adjusted hazard ratio for dysglycemia in women with PCOS was 1.87 (95% CI 1.78\u20131.97, P &amp;lt; 0.001; adjustment for age, social deprivation, BMI, ethnicity, and smoking), with increased rates of dysglycemia in all BMI subgroups. Women with PCOS and COCP use had a reduced dysglycemia risk (aOR 0.72, 95% CI 0.59\u20130.87).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In this study, limited by its retrospective nature and the use of routinely collected electronic general practice record data, which does not allow for exclusion of the impact of prescription-by-indication bias, women with PCOS exposed to COCPs had a reduced risk of dysglycemia across all BMI subgroups. Future prospective studies should be considered for further understanding of these observations and potential causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc21-0437","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T20:21:24Z","timestamp":1634242884000},"page":"2758-2766","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":17,"title":["Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study"],"prefix":"10.2337","volume":"44","author":[{"given":"Balachandran","family":"Kumarendran","sequence":"first","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, U.K."},{"name":"Department of Community and Family Medicine, Faculty of Medicine, University of Jaffna, Kokkuvil, Sri Lanka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9108-9105","authenticated-orcid":false,"given":"Michael W.","family":"O'Reilly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Republic of Ireland"},{"name":"Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradhaa","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"\u0160umilo","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Toulis","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna M.","family":"Gokhale","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrika N.","family":"Wijeratne","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arri","family":"Coomarasamy","sequence":"additional","affiliation":[{"name":"Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abd A.","family":"Tahrani","sequence":"additional","affiliation":[{"name":"Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-3556","authenticated-orcid":false,"given":"Laurent","family":"Azoulay","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health and Gerald Bronfman Department of Oncology, McGill University, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Arlt","sequence":"additional","affiliation":[{"name":"Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, U.K."},{"name":"NIHR Birmingham Biomedical Research Centre, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6816-1279","authenticated-orcid":false,"given":"Krishnarajah","family":"Nirantharakumar","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, U.K."},{"name":"Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"2022031309325973800_B1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil Steril"},{"key":"2022031309325973800_B2","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1210\/er.2012-1003","article-title":"Cardiometabolic aspects of the polycystic ovary syndrome","volume":"33","author":"Randeva","year":"2012","journal-title":"Endocr Rev"},{"key":"2022031309325973800_B3","doi-asserted-by":"crossref","first-page":"e1002542","DOI":"10.1371\/journal.pmed.1002542","article-title":"Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database","volume":"15","author":"Kumarendran","year":"2018","journal-title":"PLoS Med"},{"key":"2022031309325973800_B4","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031309325973800_B5","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/humrep\/dex294","article-title":"The prevalence of type 2 diabetes is not increased in normal-weight women with PCOS","volume":"32","author":"Pelanis","year":"2017","journal-title":"Hum Reprod"},{"key":"2022031309325973800_B6","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1210\/jc.2012-1690","article-title":"Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study","volume":"97","author":"Morgan","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031309325973800_B7","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1210\/jc.2017-01354","article-title":"Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome","volume":"102","author":"Rubin","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031309325973800_B8","doi-asserted-by":"crossref","first-page":"m3464","DOI":"10.1136\/bmj.m3464","article-title":"Menstrual cycle regularity and length across the reproductive lifespan and risk of premature mortality: prospective cohort study","volume":"371","author":"Wang","year":"2020","journal-title":"BMJ"},{"key":"2022031309325973800_B9","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1210\/jc.2013-3399","article-title":"Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione","volume":"99","author":"O\u2019Reilly","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031309325973800_B10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1210\/jc.2014-2523","article-title":"Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome","volume":"100","author":"M\u00fcnzker","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031309325973800_B11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/09513590.2017.1342793","article-title":"Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome","volume":"34","author":"Luotola","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"2022031309325973800_B12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cen.13862","article-title":"Serum testosterone, sex hormone-binding globulin and sex-specific risk of incident type 2 diabetes in a retrospective primary care cohort","volume":"90","author":"O\u2019Reilly","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2022031309325973800_B13","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jama.295.11.1288","article-title":"Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis","volume":"295","author":"Ding","year":"2006","journal-title":"JAMA"},{"key":"2022031309325973800_B14","doi-asserted-by":"crossref","first-page":"a050","DOI":"10.1210\/jendso\/bvaa050","article-title":"Endogenous testosterone levels are associated with risk of type 2 diabetes in women without established comorbidity","volume":"4","author":"Rasmussen","year":"2020","journal-title":"J Endocr Soc"},{"key":"2022031309325973800_B15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41591-020-0751-5","article-title":"Using human genetics to understand the disease impacts of testosterone in men and women","volume":"26","author":"Ruth","year":"2020","journal-title":"Nat Med"},{"key":"2022031309325973800_B16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/humrep\/dez255","article-title":"A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial","volume":"35","author":"Amiri","year":"2020","journal-title":"Hum Reprod"},{"key":"2022031309325973800_B17","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2002-021528","article-title":"A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills","volume":"88","author":"Diamanti-Kandarakis","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031309325973800_B18","first-page":"CD006133","article-title":"Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus","volume":"18","author":"Lopez","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031309325973800_B19","first-page":"251","article-title":"Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates","volume":"19","author":"Blak","year":"2011","journal-title":"Inform Prim Care"},{"key":"2022031309325973800_B20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12882-018-0834-4","article-title":"Risk of chronic kidney disease in young adults with impaired glucose tolerance\/impaired fasting glucose: a retrospective cohort study using electronic primary care records","volume":"19","author":"Jadhakhan","year":"2018","journal-title":"BMC Nephrol"},{"key":"2022031309325973800_B21","doi-asserted-by":"crossref","first-page":"e012461","DOI":"10.1136\/bmjopen-2016-012461","article-title":"Diagnosis and management of polycystic ovary syndrome in the UK (2004-2014): a retrospective cohort study","volume":"6","author":"Ding","year":"2016","journal-title":"BMJ Open"},{"key":"2022031309325973800_B22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.fertnstert.2017.09.034","article-title":"Does the risk of diabetes and heart disease in women with polycystic ovary syndrome lessen with age?","volume":"108","author":"Azziz","year":"2017","journal-title":"Fertil Steril"},{"key":"2022031309325973800_B23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.steroids.2017.12.009","article-title":"Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome","volume":"130","author":"Echibur\u00fa","year":"2018","journal-title":"Steroids"},{"key":"2022031309325973800_B24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/aje\/kwv445","article-title":"Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies","volume":"184","author":"Karim","year":"2016","journal-title":"Am J Epidemiol"},{"key":"2022031309325973800_B25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/EDE.0b013e3182093a0f","article-title":"Time-window bias in case-control studies: statins and lung cancer","volume":"22","author":"Suissa","year":"2011","journal-title":"Epidemiology"},{"key":"2022031309325973800_B26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S0047279400020341","article-title":"Deprivation","volume":"16","author":"Townsend","year":"1987","journal-title":"J Soc Policy"},{"key":"2022031309325973800_B27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/pubmed\/fdh193","article-title":"How accurate are Townsend Deprivation Scores as predictors of self-reported health? A comparison with individual level data","volume":"27","author":"Adams","year":"2005","journal-title":"J Public Health (Oxf)"},{"key":"2022031309325973800_B28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dc20-1027","article-title":"Social deprivation and incident diabetes-related foot disease in patients with type 2 diabetes: a population-based cohort study","volume":"44","author":"Riley","year":"2021","journal-title":"Diabetes Care"},{"key":"2022031309325973800_B29","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/pds.1770","article-title":"Creating medical and drug code lists to identify cases in primary care databases","volume":"18","author":"Dav\u00e9","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022031309325973800_B30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"Nishida","year":"2004","journal-title":"Lancet"},{"key":"2022031309325973800_B31","doi-asserted-by":"crossref","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"2022031309325973800_B32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/humrep\/dew329","article-title":"Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective, population-based cohort study","volume":"32","author":"Ollila","year":"2017","journal-title":"Hum Reprod"},{"key":"2022031309325973800_B33","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1210\/jc.2014-3886","article-title":"The potential implications of a PCOS diagnosis on a woman\u2019s long-term health using data linkage","volume":"100","author":"Hart","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031309325973800_B34","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2337\/dc18-1738","article-title":"The impact of obesity on the incidence of type 2 diabetes among women with polycystic ovary syndrome","volume":"42","author":"Kakoly","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031309325973800_B35","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/humrep\/dev166","article-title":"Screening for dysglycaemia by oral glucose tolerance test should be recommended in all women with polycystic ovary syndrome","volume":"30","author":"Li","year":"2015","journal-title":"Hum Reprod"},{"key":"2022031309325973800_B36","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/humrep\/den090","article-title":"Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome","volume":"23","author":"Cheung","year":"2008","journal-title":"Hum Reprod"},{"key":"2022031309325973800_B37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1530\/EC-17-0253","article-title":"Testosterone level and risk of type 2 diabetes in men: a systematic review and meta-analysis","volume":"7","author":"Yao","year":"2018","journal-title":"Endocr Connect"},{"key":"2022031309325973800_B38","first-page":"2108","article-title":"Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome","volume":"82","author":"Ehrmann","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031309325973800_B39","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1210\/jc.2017-00947","article-title":"AKR1C3-mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome","volume":"102","author":"O\u2019Reilly","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031309325973800_B40","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2337\/db07-0275","article-title":"Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome","volume":"56","author":"Skov","year":"2007","journal-title":"Diabetes"},{"key":"2022031309325973800_B41","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1210\/jc.2018-01771","article-title":"Molecular mechanisms in skeletal muscle underlying insulin resistance in women who are lean with polycystic ovary syndrome","volume":"104","author":"Hansen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031309325973800_B42","doi-asserted-by":"crossref","first-page":"e98607","DOI":"10.1172\/jci.insight.98607","article-title":"Androgen excess in pancreatic \u03b2 cells and neurons predisposes female mice to type 2 diabetes","volume":"3","author":"Navarro","year":"2018","journal-title":"JCI Insight"},{"key":"2022031309325973800_B43","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2337\/db20-0228","article-title":"Intracrine testosterone activation in human pancreatic \u03b2-cells stimulates insulin secretion","volume":"69","author":"Xu","year":"2020","journal-title":"Diabetes"},{"key":"2022031309325973800_B44","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s12020-016-0972-z","article-title":"Long-term effects of oral contraceptives on the prevalence of diabetes in post-menopausal women: 2007-2012 KNHANES","volume":"53","author":"Kim","year":"2016","journal-title":"Endocrine"},{"key":"2022031309325973800_B45","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/09513590.2021.1932802","article-title":"The use of oral contraceptive is inversely associated with the risk of type 2 diabetes mellitus among middle-aged women","volume":"37","author":"Yao","year":"2021","journal-title":"Gynecol Endocrinol"},{"key":"2022031309325973800_B46","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/BF00401427","article-title":"Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women","volume":"35","author":"Rimm","year":"1992","journal-title":"Diabetologia"},{"key":"2022031309325973800_B47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/humrep\/deq301","article-title":"The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies","volume":"26","author":"Halperin","year":"2011","journal-title":"Hum Reprod"},{"key":"2022031309325973800_B48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/humupd\/dmx039","article-title":"Combined oral contraceptives and\/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis","volume":"24","author":"Luque-Ram\u00edrez","year":"2018","journal-title":"Hum Reprod Update"},{"key":"2022031309325973800_B49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2147\/TCRM.S6864","article-title":"Use of ethinylestradiol\/drospirenone combination in patients with the polycystic ovary syndrome","volume":"4","author":"Mathur","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"2022031309325973800_B50","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer","volume":"9","author":"Rice","year":"2019","journal-title":"Front Oncol"},{"key":"2022031309325973800_B51","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bcp.12653","article-title":"NSAIDs and spontaneous abortions - true effect or an indication bias?","volume":"80","author":"Daniel","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2022031309325973800_B52","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum Reprod"},{"key":"2022031309325973800_B53","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/humupd\/dmy007","article-title":"Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression","volume":"24","author":"Kakoly","year":"2018","journal-title":"Hum Reprod Update"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/12\/2758\/631597\/dc210437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/12\/2758\/631597\/dc210437.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T06:43:13Z","timestamp":1647153793000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/44\/12\/2758\/138480\/Polycystic-Ovary-Syndrome-Combined-Oral"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,10,15]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc21-0437","relation":{"has-preprint":[{"id-type":"doi","id":"10.2337\/figshare.16608068","asserted-by":"object"},{"id-type":"doi","id":"10.2337\/figshare.16608068.v1","asserted-by":"object"}]},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]}}}